A Trial of ABI-010 & ABI-007 in Patients With Advanced Non-Hematologic Malignancies
Withdrawn before enrolling · Phase 1
Conditions studied: Solid Tumor
In brief
To determine MTD and DLT of ABI-010 given weekly every three weeks followed by one week of rest (Cycle 1). Determine MLD and DLT in combination with ABI-007; to characterize the toxicities of ABI-010 alone and in combination with ABI-007.
Key facts
- Study ID
- NCT00820768
- Run by
- Celgene
- People needed
- 0
- Starts
- 2012-04-01
- Expected to finish
- 2014-04-01
- Last updated by the study team
- 2018-04-11
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Mayo Clinic — Rochester, Minnesota, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.